Pharmacist Discharge Medication Reconciliation Study

Medication Reconciliation Clinical Trial

Official title:

The Impact of Pharmacist Discharge Medication Reconciliation on Unintentional Medication Discrepancies From Inpatient Discharges at the Alberta Cancer Board Cross Cancer Institute

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01226589
• Other study ID #: 23851
• Status: Completed
• Phase: N/A
• First received: October 21, 2010
• Last updated: April 18, 2011
• Start date: October 2007
• Est. completion date: October 2008

Study information

• Verified date: April 2011
• Source: AHS Cancer Control Alberta
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Health Canada
• Study type: Interventional

Clinical Trial Summary

Adverse drug events can occur commonly due to medication errors during the transition of care in a health care facility. Medication reconciliation is the process of comparing medications and providing an accurate medication list as a resource for prescribers, which is currently only being done upon inpatient admission at the CCI. The purpose of this study is to see if pharmacist medication reconciliation at discharge reduces unintentional medication discrepancies for inpatient discharges.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: October 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Cancer inpatients under the care of Dr. Follett or Dr. Candler

• Cancer inpatients to be discharged from the CCI

• Patients >18 years of age

• Patients that are taking >1 medications or herbals total at home.

Exclusion Criteria:

• Cancer inpatients that are considered radioactive or in "hot rooms" (ie. Selectron patients or patients receiving radiation treatment for thyroid)

• Patients that do not remain in hospital >72 hours

• Patients without a home phone number or equivalent contact number.

• Language barrier (patients unable to speak or understand English).

• Patients that are readmitted and already included into the study.

Study Design

Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Medication Reconciliation

Intervention

Procedure:
• MRS

Locations

Country	Name	City	State
Canada	Cross Cancer Institute	Edmonton	Alberta

Sponsors (1)

Lead Sponsor	Collaborator
Alberta Health Services

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	MRS Correlation with Treatment Response.	The percentage of patients with at least one unintentional medication discrepancy after discharge from the Cross Cancer Institute	up to 1 year
Secondary	Correlation with Tumor Stage	The amount of medication discrepancies after discharge that has the potential to cause moderate harm to severe harm.	up to 1 year
Secondary	The frequency of each type of unintentional medication discrepancies.